X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (85) 85
female (81) 81
index medicus (59) 59
oncology (44) 44
animals (41) 41
mice (34) 34
chemistry (33) 33
metallurgy (33) 33
adult (31) 31
cell line, tumor (29) 29
ovarian cancer (29) 29
ovarian neoplasms - pathology (27) 27
middle aged (25) 25
aged (24) 24
obstetrics & gynecology (24) 24
mice, nude (21) 21
cancer (20) 20
pregnancy (18) 18
chemotherapy (15) 15
xenograft model antitumor assays (15) 15
ovarian neoplasms - metabolism (14) 14
expression (13) 13
health aspects (13) 13
male (13) 13
mice, inbred balb c (13) 13
ovarian neoplasms - drug therapy (13) 13
analysis (12) 12
carcinoma (12) 12
electricity (12) 12
performing operations (12) 12
prognosis (12) 12
retrospective studies (12) 12
transporting (12) 12
apparatus therefor (11) 11
article (11) 11
basic electric elements (11) 11
capacitors (11) 11
capacitors, rectifiers, detectors, switching devices orlight-sensitive devices, of the electrolytic type (11) 11
cells (11) 11
cervical cancer (11) 11
compositions based thereon (11) 11
electrolytic or electrophoretic processes (11) 11
organic macromolecular compounds (11) 11
survival (11) 11
their preparation or chemical working-up (11) 11
treatment outcome (11) 11
body details or kinds of railway vehicles (10) 10
cell proliferation - drug effects (10) 10
microbiology (10) 10
ovarian neoplasms - genetics (10) 10
railways (10) 10
research (10) 10
aged, 80 and over (9) 9
apoptosis (9) 9
beer (9) 9
biochemistry (9) 9
biochemistry & molecular biology (9) 9
cell proliferation (9) 9
cisplatin (9) 9
enzymology (9) 9
mutation or genetic engineering (9) 9
neoplasm invasiveness (9) 9
neoplasm staging (9) 9
obstetrics and gynecology (9) 9
spirits (9) 9
surgery (9) 9
vinegar (9) 9
wine (9) 9
activation (8) 8
angiogenesis (8) 8
cancer therapies (8) 8
cell biology (8) 8
gene expression regulation, neoplastic (8) 8
multidisciplinary sciences (8) 8
peritoneal neoplasms - secondary (8) 8
phosphorylation (8) 8
trial (8) 8
tumors (8) 8
antineoplastic agents - pharmacology (7) 7
breast-cancer (7) 7
compositions thereof (7) 7
culture media (7) 7
disease models, animal (7) 7
disease progression (7) 7
dose-response relationship, drug (7) 7
electrolytic or electrophoretic processes for the productionof compounds or non-metals (7) 7
endometrial cancer (7) 7
gene expression (7) 7
growth (7) 7
hysterectomy (7) 7
in-vitro (7) 7
invasion (7) 7
medicine & public health (7) 7
metastasis (7) 7
microorganisms or enzymes (7) 7
microrna (7) 7
organic chemistry (7) 7
ovarian neoplasms - enzymology (7) 7
paclitaxel (7) 7
propagating, preserving or maintaining microorganisms (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 05/2010, Volume 465, Issue 7297, pp. 492 - 496
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 01/2017, Volume 15, Issue 1, pp. 78 - 92
Journal Article
Journal Article
Cancers, ISSN 2072-6694, 07/2017, Volume 9, Issue 7, p. 83
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2015, Volume 5, Issue 1, p. 18217
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2009, Volume 15, Issue 17, pp. 5404 - 5413
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 505 - 505
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, p. e0118080
Ovarian cancer remains the most lethal gynecologic cancer and new targeted molecular therapies against this miserable disease continue to be challenging. In... 
M2 MACROPHAGES | METASTASIS | ASCITES | TUMOR PROGRESSION | PATHWAY | MULTIDISCIPLINARY SCIENCES | IN-VIVO | ANTIBODY | EXPRESSION | CELL CARCINOMA | TOCILIZUMAB | Vascular Endothelial Growth Factor A - biosynthesis | Prognosis | Humans | Middle Aged | Molecular Targeted Therapy | Lipopolysaccharide Receptors - metabolism | Young Adult | Neoplasm Grading | Aged, 80 and over | Adult | Female | Ovarian Neoplasms - metabolism | Interleukin-6 - metabolism | Ovarian Neoplasms - drug therapy | Gene Expression | Macrophages - pathology | Paracrine Communication | Ovarian Neoplasms - diagnosis | Receptors, Interleukin-6 - genetics | Immunophenotyping | Cell Movement - drug effects | Macrophages - metabolism | Phenotype | Interleukin-6 - pharmacology | Models, Biological | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | CD11b Antigen - metabolism | Neoplasm Staging | Receptors, Interleukin-6 - metabolism | Viral antibodies | Interleukins | Antibodies | Comparative analysis | Health aspects | Ovarian cancer | Cell proliferation | Therapy | Biotechnology | Ovarian carcinoma | Disease | Interleukin | Paracrine signalling | Metastasis | Macrophages | CD14 antigen | Cancer therapies | Interleukin 6 | Pretreatment | University graduates | Medical research | CD11b antigen | Cytokines | Gynecology | Gene expression | Epithelium | Patients | Obstetrics | Molecular chains | Medicine | Cell lines | Hormone replacement therapy | University faculty | Ascites | Binding sites | Cancer | Peritoneum
Journal Article
Placenta, ISSN 0143-4004, 10/2016, Volume 46, p. 116
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 3, p. e0151050
Objective The objective of this study was to evaluate the antitumor effects of lurbinectedin as a single agent or in combination with existing anticancer... 
RESISTANT | IRINOTECAN HYDROCHLORIDE CPT-11 | NUCLEOTIDE-EXCISION-REPAIR | SOLID TUMORS | CISPLATIN | MULTIDISCIPLINARY SCIENCES | THERAPEUTIC TARGET | TOPOTECAN | TRABECTEDIN | PHASE-I | CANCER | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Ovarian Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Female | Ovary - drug effects | Paclitaxel - administration & dosage | Carbolines - therapeutic use | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Ovary - pathology | Carbolines - administration & dosage | Paclitaxel - therapeutic use | Drug Synergism | Animals | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Adenocarcinoma, Clear Cell - pathology | Mice | Adenocarcinoma, Clear Cell - drug therapy | Complications and side effects | Anthracyclines | Chemotherapy | Dosage and administration | Research | Drug therapy | Ovarian cancer | Cancer | Biotechnology | Transcription | Clinical trials | Cancer therapies | Doxorubicin | Anticancer properties | Synergistic effects | Salvage | Antitumor agents | Platinum | Paclitaxel | Xenografts | Lesions | Drug dosages | Deoxyribonucleic acid--DNA | University graduates | Medical research | Immunoglobulins | Gynecology | Obstetrics | Cisplatin | Medicine | Studies | Irinotecan | Cell lines | Antitumor activity | Syne